Integra LifeSciences Holdings Corporation $IART Shares Sold by Paradigm Capital Management Inc. NY

Key Points

• Paradigm Capital Management Inc. has decreased its stake in Integra LifeSciences by 3.2%, now holding 1,385,200 shares, making up approximately 1.7% of its portfolio.
• Integra LifeSciences reported earnings of $0.45 per share for the most recent quarter, exceeding analyst expectations of $0.43 and generating revenues of $415.61 million.
• Several analysts have revised their price targets for Integra LifeSciences, with Wells Fargo reducing its target from $25.00 to $13.00, indicating a shift in market sentiment for the stock.

Paradigm Capital Management Inc. NY lowered its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 3.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,385,200 shares of the life sciences company's stock after selling 45,900 shares during the quarter. Integra LifeSciences accounts for about 1.7% of Paradigm Capital Management Inc. NY's portfolio, making the stock its 19th largest position. Paradigm Capital Management Inc. NY owned about 1.78% of Integra LifeSciences worth $30,461,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Wellington Management Group LLP lifted its position in Integra LifeSciences by 10.4% during the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock valued at $60,827,000 after purchasing an additional 259,987 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Integra LifeSciences by 2,418.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock worth $39,581,000 after acquiring an additional 1,728,480 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in shares of Integra LifeSciences in the 4th quarter worth about $28,940,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Integra LifeSciences by 9.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company's stock worth $25,221,000 after acquiring an additional 99,348 shares during the last quarter. Finally, Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 8.9% in the 1st quarter. Systematic Financial Management LP now owns 936,834 shares of the life sciences company's stock worth $20,601,000 after acquiring an additional 76,271 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Up 2.3%

Shares of NASDAQ IART traded up $0.35 during midday trading on Friday, hitting $16.00. The company's stock had a trading volume of 498,652 shares, compared to its average volume of 1,047,476. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13. The business's fifty day simple moving average is $13.32 and its two-hundred day simple moving average is $15.83. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -2.45, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences's revenue was down .6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Separately, JMP Securities decreased their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $18.43.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.